NASDAQ:GHRS GH Research (GHRS) Stock Price, News & Analysis $7.51 -0.79 (-9.52%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About GH Research Stock (NASDAQ:GHRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GH Research alerts:Sign Up Key Stats Today's Range$7.02▼$8.6450-Day Range$6.30▼$11.4852-Week Range$5.05▼$14.99Volume86,407 shsAverage Volume80,552 shsMarket Capitalization$390.73 millionP/E RatioN/ADividend YieldN/APrice Target$36.67Consensus RatingBuy Company OverviewGH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. GH Research Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks30th Percentile Overall ScoreGHRS MarketRank™: GH Research scored higher than 30% of companies evaluated by MarketBeat, and ranked 822nd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGH Research has only been the subject of 2 research reports in the past 90 days.Read more about GH Research's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($0.89) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GH Research is -11.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GH Research is -11.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGH Research has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GH Research's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.26% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 40.2, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently increased by 5.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.26% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 40.2, which indicates bearish sentiment.Change versus previous monthShort interest in GH Research has recently increased by 5.96%, indicating that investor sentiment is decreasing significantly. News and Social Media1.4 / 5News Sentiment-0.50 News SentimentGH Research has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for GH Research this week, compared to 1 article on an average week.MarketBeat Follows8 people have added GH Research to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GH Research's insider trading history. Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Email Address GHRS Stock News HeadlinesFDA is said to see “path forward” for ecstasy-based drugOctober 19, 2024 | msn.comGH Research (NASDAQ:GHRS) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Buy Rating Affirmed on GH Research Amid Anticipated Phase 2 Advances and Strong Market PotentialSeptember 5, 2024 | markets.businessinsider.comIrish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug TrialsSeptember 5, 2024 | msn.comMaintaining Buy Rating on GH Research Amidst CEO Transition and Promising GH001 TrialsSeptember 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for GH Research Amid Anticipated Clinical Advances and Strong LeadershipSeptember 4, 2024 | markets.businessinsider.comGH Research Names Velichka Villy Valcheva CEO - Quick FactsSeptember 3, 2024 | nasdaq.comSee More Headlines GHRS Stock Analysis - Frequently Asked Questions How have GHRS shares performed this year? GH Research's stock was trading at $5.80 at the beginning of the year. Since then, GHRS shares have increased by 29.5% and is now trading at $7.51. View the best growth stocks for 2024 here. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) released its quarterly earnings results on Tuesday, September, 3rd. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. When did GH Research IPO? GH Research (GHRS) raised $150 million in an initial public offering on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of GH Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that GH Research investors own include Baidu (BIDU), Shopify (SHOP), Bristol-Myers Squibb (BMY), Zoom Video Communications (ZM), Atai Life Sciences (ATAI), CRISPR Therapeutics (CRSP) and Caesars Entertainment (CZR). Company Calendar Last Earnings9/03/2024Today10/23/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GHRS CUSIPN/A CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$36.67 High Stock Price Target$40.00 Low Stock Price Target$31.00 Potential Upside/Downside+388.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-16.39% Return on Assets-15.83% Debt Debt-to-Equity RatioN/A Current Ratio19.60 Quick Ratio19.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book1.52Miscellaneous Outstanding Shares52,028,000Free Float30,384,000Market Cap$390.73 million OptionableOptionable Beta0.79 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:GHRS) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.